Patent ID: 11872225
Assignee: AGIOS PHARMACEUTICALS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. A method of treating a disease associated with the aberrant activity of PKM2 in a subject in need thereof comprising administering an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein:, Q is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
R1 is hydrogen, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, —ORo1, —C(═O)Rc1, or a nitrogen protecting group;
L1 is a bond, optionally substituted alkylene, —O—, —S—, —S—CH2—, —S(═O)CH2—, —S(═O)2CH2—, —NR—, —NR3C(═O)—, —C(═O)NR3—, C(═O)—, —OC(═O)—, —C(═O)O—, —NR3C(═O)O—, —OC(═O)NR3—, —NR3C(═O)NR3—, —OC(R4)2—, —C(R4)2O—, —NR3C(R4)2—, —C(R4)2NR3—, —S(═O)2—, —S(═O)—, —S(═O)2O—, —OS(═O)2—, —S(═O)O—, —OS(═O)—, —S(═O)2NR3—, —NR3S(═O)2—, —S(═O)NR3—, —NR3S(═O)—, —NR3S(═O)2O—, —OS(═O)2NR3—,
NR3S(═O)O—, —OS(═O)NR3—, or —S(═O)(═NR3)—, wherein the point of the attachment to R2 is on the left-hand side;
L2 is a bond, optionally substituted alkylene, —C(═O)—, —S(═O)2—, or —S(═O)—, wherein the point of the attachment to Q is on the right-hand side;
R2 is hydrogen, halogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or a nitrogen protecting group when L1 is —NR—, —NR3C(═O)—, —NR3C(═O)O—, —NR3C(R4)2—, —NR3S(═O)2—, —NR3S(═O)—, —NR3C(═O)NR3—, —NR3S(═O)2O—, or —NR3S(═O)O—, an oxygen protecting group when L1 is —O—, —OC(═O)—, —OC(═O)NR3—, —OC(R4)2—, —OS(═O)2—, —OS(═O)2NR3—, —OS(═O)NR3—, or —OS(═O)—, or a sulfur protecting group when L1 is —S—;
each instance of R3 is independently hydrogen, —ORo2, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a nitrogen protecting group;
each instance of Ro1 and Ro2 is independently hydrogen, optionally substituted alkyl, or an oxygen protecting group;
each instance of Rc1 is independently optionally substituted alkyl or —N(Rcn)2 wherein each instance of Rcn is independently hydrogen, —C1-6 alkyl, or a nitrogen protecting group; and
each instance of R4 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
wherein the disease is selected from cancer, obesity, a diabetic disease, atherosclerosis, coronary artery disease (CAD), Bloom Syndrome (BS), and an autoimmune disease.